You are viewing the site in preview mode
Skip to main content
|
No
|
Age (years)/Gender
|
Smoking history (pack-years)
|
Pathological type/Tumor stage
|
Treatment modality
|
Induction chemotherapy regimen
|
Radiotherapy dose (Gy/fraction)
|
Percentage of lung volume affected in subclinical ILD (%)
|
Grade of RP
|
|---|
|
1
|
68/Male
|
40
|
Squamous cell carcinoma/IIIB
|
RT
|
Cisplatin + gemcitabine
|
44.0/22
|
≥ 25
|
4
|
|
2
|
77/Male
|
50
|
Squamous cell carcinoma/IIIB
|
RT
|
Carboplatin + gemcitabine
|
49.5/22
|
≥ 25
|
5
|
|
3
|
67/Male
|
No
|
Squamous cell carcinoma/postoperative stump recurrence
|
RT
|
Cisplatin + gemcitabine
|
24.0/12
|
< 25
|
2
|
|
4
|
63/Male
|
80
|
Adenocarcinoma/IIIB
|
RT
|
Cisplatin + gemcitabine
|
58.0/29
|
< 25
|
3
|
|
5
|
65/Male
|
40
|
NSCLC/IIIB
|
RT
|
Cisplatin + vinorelbine
|
38.0/19
|
< 25
|
4
|
|
6
|
69/Male
|
50
|
Squamous cell carcinoma/IIIB
|
RT
|
Carboplatin + gemcitabine
|
38.0/19
|
≥ 25
|
5
|
|
7
|
52/Male
|
60
|
Adenocarcinoma/IIIB
|
RT
|
Cisplatin + pemetrexed
|
30.0/15
|
< 25
|
2
|
|
8
|
67/Male
|
No
|
SCLC/IIIB
|
RT
|
Carboplatin + etoposide
|
40.0/20
|
< 25
|
2
|
- RP, radiation pneumonitis; ILD, interstitial lung disease; RT, radiation therapy; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer
